PMID: 11899308Mar 20, 2002Paper

Vancomycin intermediate-resistant Staphylococcus aureus (VISA)

Orthopaedic Nursing
N C Miller, R C Rudoy

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has been an infectious disease problem since the early 1980s and until recently was uniformly susceptible to vancomycin, the drug known as the "last resort." Recent reports indicate that Staphylococcus aureus has continued to mutate and has developed intermediate resistance to vancomycin (VISA). This article lists some of the potential clinical manifestations of Staphylococcus aureus as well as a possible explanation of the phenomenon of antibiotic resistance. The reported cases of VISA are reviewed, and intervention strategies for prevention and control are discussed.

Citations

Oct 13, 2001·Trends in Microbiology·K HiramatsuT Ito
Sep 30, 2014·Physiotherapy Theory and Practice·G Shankar GaneshChittaranjan Mishra

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.